In the decades since the introduction of Bevacizumab, more and more anti-angiogenic therapies have become available together with other targeted therapies targeting EGFR, kras, nras, and BRAF (for wild-type metastatic disease), or BRAF and HER2 (for metastatic colorectal cancer exhibiting these types of mutations). The gene discussed is BRAF; the disease is metastatic colorectal cancer.